Quarterly report pursuant to Section 13 or 15(d)

INTELLECTUAL PROPERTY/ LICENSING RIGHTS

v3.19.2
INTELLECTUAL PROPERTY/ LICENSING RIGHTS
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Note 6 - INTELLECTUAL PROPERTY/ LICENSING RIGHTS

On August 20, 2018, the Company purchased all the worldwide rights of Naltrexone Implants formula(s) with exception of New Zealand and Australia from Trinity Compound Solutions, Inc for $10,000 and 20,000 shares of its common stock for an aggregate purchase price of $236,000.

 

On October 12, 2018 the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals Inc. acquired six patent families for sustained delivery platforms for the local delivery of biologic and small molecule drugs for an aggregate purchase price of $15,200.